Tomomi Shijo

Tomomi Shijo

Auto-generated profile, based on publicly available information

Tomomi Shijo

Department of Neurology Shodo‐Kai Southern Tohoku General Hospital Iwanuma Miyagi Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2017 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
TSTomomi Shijo
Tomomi Shijo
HWHitoshi Warita
Hitoshi Warita
NSNaoki Suzuki
Naoki Suzuki
YKYasuo Kitajima
Yasuo Kitajima
KIKensuke Ikeda
Kensuke Ikeda
MAMasashi Aoki
Masashi Aoki

15 August 2023 in Internal Medicine
Verified
Journal Article
Open access
PDF file
TKTakafumi Kubota
Takafumi Kubota
TSTomomi Shijo
Tomomi Shijo
KIKensho Ikeda
Kensho Ikeda
YMYoshihiko Mitobe
Yoshihiko Mitobe
SUShu Umezawa
Shu Umezawa
MAMasashi Aoki
Masashi Aoki
We herein report a rare case of distal chronic inflammatory demyelinating polyneuropathy (CIDP) following coronavirus disease 2019 (COVID-19) vaccination. A 39-year-old woman with a solitary plasmacytoma developed general weakness 7 days after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine, which had progressed for 3 months. A neurological examination revealed limb weakness with areflexia. Serological tests identified the presence of IgG antibodies against anti-GM1 and anti-GM2 gangliosides. Comprehensive evaluations met the criteria of distal CIDP. Intravenous immunoglobulin, intravenous methylprednisolone, oral prednisolone, and plasma exchange were administered, and she gradually improved. Physicians should be aware of CIDP as a rare complication of COVID-19 vaccination.

13 March 2026 in The FASEB Journal
Verified
Journal Article
Open access
NNNaoko Nakamura
Naoko Nakamura
NSNaoki Suzuki
Naoki Suzuki
SKShin‐Ichiro Kanno
Shin‐Ichiro Kanno
RYRei Yamanaka
Rei Yamanaka
HOHiroya Ono
Hiroya Ono
MAMasashi Aoki
Masashi Aoki
Dysferlinopathy is an adult‐onset form of muscular dystrophy caused by mutations in the dysferlin gene and is inherited in an autosomal recessive manner. Dysferlin is primarily known for its role in plasma membrane repair. Although several proteins associated with dysferlin have been identified, many aspects of its signaling pathways and protein–protein interactions remain unclear. Here, we focused on the region between the third and fourth C2 domains, where frequent genetic mutations occur and functional domains are concentrated, and identified the protein kinase CK2α (formerly known as casein kinase 2) as a novel dysferlin‐binding protein. CK2α was found to accumulate at membrane injury sites along with dysferlin in mouse skeletal muscle, and membrane repair was delayed in CK2α knockout cells. Furthermore, overexpression of CK2α in dysferlin‐deficient mouse muscle led to improved membrane repair. Additionally, we revealed that CK2α plays a role in phosphorylating annexin A1, which is known to bind to dysferlin and is involved in plasma membrane repair. Our results indicated that CK2α controls membrane repair by participating in the phosphorylation of annexin A1. The molecular interplay among dysferlin, CK2α, and phosphorylated annexin A1 represents a novel therapeutic target for promoting membrane repair.

14 August 2026 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
TSTomomi Shijo
Tomomi Shijo
NSNaoki Suzuki
Naoki Suzuki
HWHitoshi Warita
Hitoshi Warita
KIKensuke Ikeda
Kensuke Ikeda
MKMasaaki Kato
Masaaki Kato
MAMasashi Aoki
Masashi Aoki

23 March 2026 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
NNNaoko Nakamura
Naoko Nakamura
NSNaoki Suzuki
Naoki Suzuki
SKShin‐Ichiro Kanno
Shin‐Ichiro Kanno
RYRei Yamanaka
Rei Yamanaka
HOHiroya Ono
Hiroya Ono
MAMasashi Aoki
Masashi Aoki
The cover image is based on the article A Novel Dysferlin-Binding Kinase CK2α Promotes Plasma Membrane Repair in Dysferlinopathy by Naoko Nakamura et al., https://doi.org/10.1096/fj.202500773RRR.